reports
BenevolentAI Announces Further Success With AstraZeneca Collaboration ...
LONDON--(BUSINESS WIRE)-- BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI. Novel target for Heart Failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca First target to be selected from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of Target...
BenevolentAI: Result of Annual General Meeting
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery announces that all resolutions proposed at its Annual General Meeting held today were duly passed. The voting results will be made available shortly on the Company’s website (), where the full documentation regarding the AGM can also be found. In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the Board of the Company as Non-Executiv...
- Ahmed Ben Salem
- Damien Choplain
- Oussema Denguir
BenevolentAI : Focus on the development of partnerships and the propri...
>A reduction to the headcount of around 30% - This morning, Benevolent announced an update to its strategic road map from which we note the following key elements: 1/ the group confirms that priority is given to its research activity and the development of partnerships on its AI platform with the aim of discovering new treatments as well as advancing and developing its pipeline of proprietary assets, 2/ the abandoning of the strategic option of rolling out an activity...
- Ahmed Ben Salem
- Damien Choplain
- Oussema Denguir
BenevolentAI : Focus sur le développement de partenariats et sur son p...
>Une réduction d’environ 30% des effectifs - Benevolent a communiqué ce matin une mise à jour de sa feuille de route stratégique suite à laquelle nous retenons les éléments suivants : 1/ la société a confirmé donner la priorité à son activité de recherche et de conclusion de partenariats autour de sa plateforme d’IA pour la découverte de nouveaux traitements ainsi qu’à l’avancement et au développement de son pipeline d’actifs propriétaires, 2/ l’abandon de l’option st...
BenevolentAI Provides an Update on Its Business Priorities
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities. Going forward the Company will focus on its AI-driven drug discovery collaboration and proprietary pipeline revenue generating pillars, following recent successes in these areas. The Board believes this focus will likely bring the greatest potential return for shareholders. Following completion of the market assessment of its Knowledge Exploratio...
BenevolentAI: Publication of the Revised Agenda for the 2024 AGM
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of the Revised Agenda for its Annual General Meeting set to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 AGM”) (the “Revised Agenda”). The Revised Agenda, the revised proxy form and all other meeting documentation are now available on the Company’s website () and at the Company’s registered office. The shareholders enti...
Proposed Changes to BenevolentAI’s Board Composition
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that following extensive discussions with Mr. Kenneth Mulvany, founder and former Chairman of BenevolentAI Limited and a Non-Executive Director of BenevolentAI, several resolutions will be put forward at the Company’s upcoming Annual General Meeting (“AGM”) relating to the future membership of the board of the Company (“the Board”). Mr. Mulvany has submitted four resolutions to be added to the agenda o...
- Damien Choplain
- Oussema Denguir
- Stephane Beyazian
- Damien Choplain
- Oussema Denguir
BenevolentAI : Safety profile validated for BEN-8744
>Positive phase I results - BenevolentAI announced positive phase I results for BEN-8744 (PDE10 inhibitor), the main aim being to validate the safety and tolerance profile in 54 healthy volunteers. The trial therefore achieved its aim by demonstrating that BEN-8744 was safe and well tolerated without any adverse effects affecting the central nervous systems, one of the risks associated with PDE10 inhibitors previously in clinical development. Moreover, the product’s p...
- Damien Choplain
- Oussema Denguir
BenevolentAI : Profil de sécurité validé pour BEN-8744
>Résultats positifs de phase I - BenevolentAI annonce des résultats de phase positifs pour BEN-8744 (inhibiteur de la PDE10) qui avait pour objectif principal de valider le profil de sécurité et de tolérance chez 54 volontaires sains. L’étude a donc atteint son objectif en démontrant que BEN-8744 était sûr et bien toléré sans effets indésirables affectant le système nerveux central, un des risques associés aux inhibiteurs de la PDE10 précédemment en développement clin...
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Dat...
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers. BEN-8744 is an orally administered, peripherally-restricted PDE10 inhibitor being developed as a potential first-in-class treatment for patients with moderate to severe ulcerative colitis (UC) The Phase Ia study met its primary objective. BEN-8744 was safe and well tolerated, wit...
BenevolentAI Appoints New Chief Technology Officer
LONDON--(BUSINESS WIRE)-- BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family. The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer. James will join at the beginning of April and will be based out of the UK, reporting into BenevolentAI’s CEO, ...
BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice
LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of its Annual Report and Accounts for the year ended 31 December 2023 (the “2023 Annual Report”) and the convening notice for its annual general meeting to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 AGM”) (the “2024 AGM Notice”). The 2023 Annual Report, the 2024 AGM Notice, the amended Remuneration Policy of the Company...
- Benoit Valleaux
- Steven Gould
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 03/14/2024
Banks tick all the boxes in the market’s current configuration: search for discounted sectors, cyclical momentum, sectors driven by long-term interest rates that remain high and shareholder returns through very high dividend yields. Technical analysis reveals a strong conviction since early March, and this should continue. We prefer banks in southern Europe, where the macro outlook is brighter. Alongside CaixaBank, which we are maintaining in our list of European Large Cap stocks, we ...
CSGN CREDIT SUISSE GROUP AG
UBSN UBS GROUP AG
BNP BNP PARIBAS SA CLASS A
DBK DEUTSCHE BANK AG
CBK COMMERZBANK AG
BFIT BASIC-FIT NV
PBB DEUTSCHE PFANDBRIEFBANK AG
IDL ID LOGISTICS GROUP
INF INFOTEL SA
GLE SOCIETE GENERALE S.A. CLASS A
KBC KBC GROUP N.V.
LXS LANXESS AG
ASY ASSYSTEM SA
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
CDA COMPAGNIE DES ALPES SA
ISP INTESA SANPAOLO S.P.A.
BCP BANCO COMERCIAL PORTUGUES S.A.
SHA SCHAEFFLER AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ERG ERG S.P.A.
BKT BANKINTER SA
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
UCG UNICREDIT S.P.A.
CABK CAIXABANK SA
INGA ING GROEP NV
SAN BANCO SANTANDER S.A.
UNI UNICAJA BANCO S.A.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
DMP DERMAPHARM HOLDING SE
MOR MORPHOSYS AG
SAB BANCO DE SABADELL SA
2CRSI 2CRSI SA
TITC TITAN CEMENT INTERNATIONAL N.V.
SRAIL STADLER RAIL AG
SFQ SAF-HOLLAND SE
BLV BELIEVE SA
BAI BENEVOLENTAI
- Jerôme Bodin
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 14/03/2024
Les banques cochent toutes les cases de la configuration de marché actuelle : recherche de secteurs décotés, momentum cyclique, secteurs portés par des taux longs qui restent hauts, retour à l’actionnaire via un très haut dividend yield. L’analyse technique montre une forte conviction depuis début mars, qui devrait se poursuivre. Nous favorisons les banques du sud de l’Europe, à la macro plus avenante. Aux côtés de CaixaBank, que nous conservons dans notre liste de valeurs Large Caps ...
IDL ID LOGISTICS GROUP
INF INFOTEL SA
LXS LANXESS AG
ASY ASSYSTEM SA
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
CDA COMPAGNIE DES ALPES SA
SHA SCHAEFFLER AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ERG ERG S.P.A.
DMP DERMAPHARM HOLDING SE
MOR MORPHOSYS AG
2CRSI 2CRSI SA
TITC TITAN CEMENT INTERNATIONAL N.V.
SRAIL STADLER RAIL AG
SFQ SAF-HOLLAND SE
BLV BELIEVE SA
BAI BENEVOLENTAI
- Damien Choplain
- Oussema Denguir
BenevolentAI : No surprises in the FY 2023 publication
>A year marked by cost-cutting - This morning, BenevolentAI announced its preliminary FY 2023 results. We note the following points: 1/ revenue was at £ 7.3m (-31% y-o-y) marked by both lower revenue from the collaboration with AstraZeneca and including receipts from the recent collaboration with Merck, 2/ a decrease in R&D spend to -£ 57m (-12% y-o-y) and 3/ a 30% reduction in SG&A spend to -£ 23.5m in line with the cost-cutting strategy announced in 2023. The adjus...
- Damien Choplain
- Oussema Denguir
BenevolentAI : Publication FY 2023 sans grandes surprises
>Un exercice marqué par la réduction des coûts - BenevolentAI a communiqué ce matin les résultats préliminaires pour l’année 2023. Nous en soulignons les points suivants : 1/ les revenus sont à 7.3 M£ (-31% yoy) marqué à la fois par la baisse des revenus provenant de la collaboration avec AstraZeneca et incluant les encaissements issus de la récente collaboration avec Merck, 2/ une diminution des dépenses R&D à -57 M£ (-12% yoy) qui et 3/ une réduction des dépenses SG...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.